ArticleFrontiers in immunology2026
Expanding the clinical spectrum of pediatric CASPR2 antibody-associated autoimmune encephalitis: a multicenter case series.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Contactin-associated protein-like 2 (CASPR2) antibody-associated autoimmune encephalitis is rare in children, and available clinical data are limited. Our aim is to describe the clinical spectrum, diagnostic findings, treatment, and outcomes of all pediatric CASPR2 antibody-associated encephalitis patients reported in Hungary. Methods: We present a retrospective case series including nine pediatric patients diagnosed with CASPR2 antibody-associated encephalitis across five centers. Clinical, laboratory, imaging, electrophysiological findings, treatment, and follow-up data were collected. Results: The mean age at onset was 4.1 ± 2.6 years. All patients were serum CASPR2 antibody-positive; two had CSF positivity. The most common symptoms included sleep disorder, irritability, aggressiveness, hypertension, tachycardia, abdominal pain, itching, exanthema, and weight loss. No specific abnormalities were detected on MRI, EEG, or laboratory testing. Immunotherapy led to favorable outcomes in nearly all patients, with one relapse during follow-up. Discussion: This series expands the clinical spectrum of CASPR2-associated autoimmune encephalitis in children. The presenting symptoms in pediatric patients may differ not only from those observed in adults but also from other forms of autoimmune encephalitis. The diagnostic process is especially complex due to the variability and age-related evolution of clinical manifestations, which can be difficult to recognize in younger children and commonly contribute to diagnostic delay. Early recognition and immunotherapy are associated with favorable prognosis. This case series underscores the importance of recognizing the diverse spectrum of presenting symptoms and highlights the need for raising awareness of the clinical variability. Larger prospective studies are needed to define diagnostic, therapeutic strategies and prognostic factors in the pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.